CytoDyn Statistics
Total Valuation
CytoDyn has a market cap or net worth of 275.42 million. The enterprise value is 290.85 million.
| Market Cap | 275.42M |
| Enterprise Value | 290.85M |
Important Dates
The next estimated earnings date is Wednesday, October 7, 2026.
| Earnings Date | Oct 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CytoDyn has 1.38 billion shares outstanding. The number of shares has increased by 3.73% in one year.
| Current Share Class | 1.38B |
| Shares Outstanding | 1.38B |
| Shares Change (YoY) | +3.73% |
| Shares Change (QoQ) | +7.33% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 0.01% |
| Float | 1.38B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -2.51 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.26
| Current Ratio | 0.26 |
| Quick Ratio | 0.22 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.58 |
| Interest Coverage | -9.22 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -90.35% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 58.22% |
| Weighted Average Cost of Capital (WACC) | 10.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -3.16M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.81% in the last 52 weeks. The beta is 1.24, so CytoDyn's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | -38.81% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 0.27 |
| Relative Strength Index (RSI) | 40.44 |
| Average Volume (20 Days) | 1,415,535 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 21.18 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -23.15M |
| Pretax Income | -42.70M |
| Net Income | -44.18M |
| EBITDA | -23.13M |
| EBIT | -23.15M |
| Earnings Per Share (EPS) | -0.03 |
Balance Sheet
The company has 11.85 million in cash and 27.28 million in debt, with a net cash position of -15.42 million or -0.01 per share.
| Cash & Cash Equivalents | 11.85M |
| Total Debt | 27.28M |
| Net Cash | -15.42M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -109.72M |
| Book Value Per Share | -0.08 |
| Working Capital | -39.85M |
Cash Flow
| Operating Cash Flow | -17.25M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 17,000 |
| Net Borrowing | -142,000 |
| Free Cash Flow | -17.25M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CytoDyn does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.73% |
| Shareholder Yield | -3.73% |
| Earnings Yield | -16.04% |
| FCF Yield | -6.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |